Geary v. Parexel International Corporation

CourtDistrict Court, N.D. California
DecidedMarch 18, 2022
Docket5:19-cv-07322
StatusUnknown

This text of Geary v. Parexel International Corporation (Geary v. Parexel International Corporation) is published on Counsel Stack Legal Research, covering District Court, N.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Geary v. Parexel International Corporation, (N.D. Cal. 2022).

Opinion

1 2 3 4 UNITED STATES DISTRICT COURT 5 NORTHERN DISTRICT OF CALIFORNIA 6 SAN JOSE DIVISION 7 8 WILLIAM JOHN GEARY, Case No. 5:19-cv-07322-EJD

9 Plaintiff, ORDER GRANTING MOTION TO DISMISS WITH LEAVE TO AMEND 10 v.

11 PAREXEL INTERNATIONAL Re: Dkt. No. 122 CORPORATION, et al., 12 Defendants.

13 14 Plaintiff William John Geary III, proceeding pro se, brings this action against Defendant 15 Parexel International Corporation (“Parexel”) and its individual officers, executives, and directors 16 (collectively, “the Individual Defendants”), asserting the following claims: (1) retaliation in 17 violation of the Sarbanes-Oxley Act of 2002 (“Sarbanes-Oxley”), 18 U.S.C. § 1514A against all 18 Defendants; (2) retaliation in violation of the Dodd-Frank Wall Street Reform and Consumer 19 Protection Act (“Dodd-Frank”), 15 U.S.C. § 78u-6 against all Defendants; (3) retaliation through 20 wrongful termination in violation of California Labor Code § 1102.5 against Parexel1; and (4) 21 wrongful termination in violation of public policy against all Defendants. Compl., Dkt. No. 1. 22 Defendants now move to dismiss the complaint under Federal Rules of Civil Procedure 12(b)(1) 23 and (6). Defs.’ Not. of Mot. and Mot. to Dismiss Plf.’s Compl. Pursuant to F.R.C.P. 12(b)(1) and 24

25 1 In the text of the Complaint, Geary lists both the third and fourth claim as “wrongful termination 26 in violation of public policy,” but on the caption of the Complaint, he describes his third claim as retaliation under California Labor Code § 1102.5 and the fourth claim as wrongful termination in 27 violation of public policy. 1 F.R.C.P. 12(b)(6) (“Mot.”), Dkt. No. 122. The Court finds the motion appropriate for decision 2 without oral argument pursuant to Civil Local Rule 7-1(b). Having considered the parties’ written 3 submissions, the Court GRANTS the motion with leave to amend. 4 I. BACKGROUND 5 Parexel is a clinical research service company headquartered in Waltham, Massachusetts, 6 with approximately 18,600 employees across 52 countries. Compl. ¶ 13. The Individual 7 Defendants consist of: Parexel co-founder, Chairman of the Board of Directors, and Chief 8 Executive Officer Josef H. von Rickenbach; President, Chief Operating Officer, and Director 9 Mark A. Goldberg, M.D.; Senior Vice President, Clinical Research Services and Director Roland 10 Andersson, Ph.D.; Senior Vice President, Chief Financial Officer, and Director Ingo Bank; Senior 11 Vice President, General Counsel, Secretary, and Director Douglas A. Batt; Parexel Informatics 12 President and Parexel Director Xavier Flinois; Senior Vice President, Clinical Research Services 13 and Director Gadi Saarony; Senior Vice President, Chief Administrative Officer, and Director Ulf 14 Schneider, Ph.D.; Senior Vice President, Clinical Research Services and Director Thomas 15 Senderovitz, M.D.; Director A. Dana Callow, Jr.; Director Patrick J. Fortune, Ph.D.; Director 16 Maykin Ho, Ph.D.; Director Eduard E. Holdener, M.D.; Director Christopher J. Lindop; Director 17 Richard L. Love; and Director Ellen M. Zane.2 Id. ¶¶ 14-15. 18 Geary is a resident of San Jose, California. Id. ¶ 13. In February 2014, Parexel hired 19 Geary to work from home as a Sr. Project Leader. Id. ¶ 8. In that role, Geary was responsible for 20 calculating and reporting accrual of recognized revenue and attesting to accuracy of expenses prior 21 to submitting them to clients for reimbursement. Id. ¶ 11. 22 In August 2014, Geary was assigned to be the Sr. Project Leader for Parexel client 23 Pharmacyclics, Inc. (“PCYC”). Id. ¶¶ 9, 19. He says he was selected to “rescue a failing project” 24 (the “PCYC Project”). Id. ¶ 19. Upon assuming leadership of the PCYC Project, Geary “reported 25

26 2 Parexel notes that only one of the Individual Defendants remains employed at or in service as a 27 Director. Mot. at 11 n.4. 1 up the hierarchy that [the] PCYC Project had serious, pre-existing issues of controls related to 2 revenue recognition and client approval of monthly invoices for payment.” Id. Specifically, for 3 the 18 months prior, PCYC had refused to authorize monthly invoices that Geary’s immediate 4 supervisor, Sr. Director Joy Yucaitis, had submitted to PCYC. Id. ¶ 20. PCYC demanded that 5 Yucaitis be removed from the PCYC Project, leading to Geary’s assignment. Id. ¶ 21. Geary says 6 that as soon as he joined the PCYC Project, he began experiencing “pressure and pre-emptive 7 retaliation to influence PCYC to authorized overstated invoices.” Id. ¶ 23. 8 On November 5, 2014, Geary reported errors in Parexel’s revenue recognition for the 9 PCYC Project “due to a lack of internal controls in revenue recognition.” Id. ¶ 24. Parexel 10 subsequently reversed $162,000 in revenue recognition. Id. ¶ 25. Shortly thereafter, beginning in 11 December 2014, Geary says that he “began receiving intense abuse, threats and coercion to ‘use 12 your credibility to influence with PCYC’ representatives” to obtain PCYC’s authorization for 13 overstated monthly invoices. Id. ¶ 26. On January 29, 2015, Geary alleges that Yucaitis publicly 14 verbally abused him at an off-site business meeting and ordered him to remove his clothing and 15 don another man’s clothing instead. Id. ¶ 28. On February 5, 2015, Geary was placed on a 16 Performance Improvement Plan (“PIP”) because he “had damaged his working relationship with 17 the Parexel Finance department.” Id. ¶ 29. The PIP stated, “Specifically, he must make progress 18 in mending fences with finance.” Id. 19 In March 2015, Geary was assigned to be the Sr. Project Leader for another Parexel client, 20 GlaxoSmithKline (“GSK”), on the “GSK Project.” Id. ¶¶ 30-31. Geary alleges that Parexel 21 finance representatives directed him to “manufacture accrual and recognize” $400,000 in revenue 22 for the GSK Project for the month of March, despite the fact that the GSK Project had been active 23 for less than 30 days, no work had been started on the project, and no revenue had accrued. Id. ¶¶ 24 32-33. According to Geary, his supervisor “made it clear to him that he was ‘expected to conform 25 to revenue projections’ and authorize the $400K revenue recognition.” Id. ¶ 34. Despite being on 26 a PIP and under a threat of termination, Geary refused to fabricate the revenue. Id. ¶¶ 34-35. 27 On April 9, 2015, Geary reported what he believes was wire fraud, investor fraud, and 1 violations of the Physicians Payment Sunshine Act through the Parexel hierarchy. Id. ¶ 36. He 2 believed that emailing manufactured financial reports to a client in order to obtain authorization 3 for payment of invoices constituted wire fraud. Id. ¶ 37. Geary also believed that manufacturing 4 revenue accrual constituted investor fraud. Id. ¶ 38. 5 On April 24, 2015, Parexel placed Geary on a leave of absence. Id. ¶ 49. Geary reported 6 his observations to the Securities and Exchange Commission (“SEC”) in May 2018. Id. ¶ 50. 7 During May and June 2015, Geary says he was pressured to sign a non-disclosure agreement but 8 refused. Id. ¶ 41. On June 30, 2015, Parexel terminated Geary’s employment, which he believes 9 was because he “refused to be complicit in wrongdoing.” Id. ¶ 42. 10 On November 29, 2015, Geary filed a complaint describing alleged fraud, retaliation, 11 malice, oppression, and racketeering at Parexel to the U.S. Department of Labor’s Occupational 12 Safety and Health Administration (“OSHA”). Id. ¶ 43.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Mendiondo v. Centinela Hospital Medical Center
521 F.3d 1097 (Ninth Circuit, 2008)
Mathieu v. Norrell Corp.
10 Cal. Rptr. 3d 52 (California Court of Appeal, 2004)
Lawson v. FMR LLC
134 S. Ct. 1158 (Supreme Court, 2014)
Prue v. Brady Company/San Diego, Inc. CA4/1
242 Cal. App. 4th 1367 (California Court of Appeal, 2015)
Artis v. District of Columbia
583 U.S. 71 (Supreme Court, 2018)
Karim Khoja v. Orexigen Therapeutics, Inc.
899 F.3d 988 (Ninth Circuit, 2018)
Romano v. Rockwell International, Inc.
926 P.2d 1114 (California Supreme Court, 1996)
Wadler v. Bio-Rad Laboratories, Inc.
141 F. Supp. 3d 1005 (N.D. California, 2015)
Safe Air for Everyone v. Meyer
373 F.3d 1035 (Ninth Circuit, 2004)

Cite This Page — Counsel Stack

Bluebook (online)
Geary v. Parexel International Corporation, Counsel Stack Legal Research, https://law.counselstack.com/opinion/geary-v-parexel-international-corporation-cand-2022.